TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15856479

Group type: EXPERIMENTAL
Intervention: Daclizumab (DZB) induction and daily mycophenolate mofetil with steroids
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard tacrolimus-based triple therapy
Number of subjects: 51
Study: 12008989

Group type: EXPERIMENTAL
Intervention: 20-week behavior modification intervention emphasizing increasing diet nutrient-density
Number of subjects: 31
Study: 9371155

Group type: EXPERIMENTAL
Intervention: Aptiganel (Cerestat)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 1827074

Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + 30 micrograms ethinyl estradiol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Desogestrel 150 micrograms + 50 micrograms ethinyl estradiol
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 2 mg + 35 micrograms ethinyl estradiol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (19 normal women, not treated)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 26
Study: 6960390

Group type: EXPERIMENTAL
Intervention: PGE2 0.5 mg three times daily and 1 mg at night
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: PGE2 and Placebo
Number of subjects: 28
Study: 31898644

Group type: EXPERIMENTAL
Intervention: CADe group (computer‐aided detection system)
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Control group (without CADe system)
Number of subjects: 1026
Study: 30589759

Group type: EXPERIMENTAL
Intervention: Eccentric Viewing Training (EVT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study: 28117385

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 872
Study: 25242512

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) reconstruction
Number of subjects: 78

Group type: COMPARATOR
Intervention: Single-bundle (SB) reconstruction
Number of subjects: 78
Study: 25066556

Group type: EXPERIMENTAL
Intervention: OCT-guided angioplasty
Number of subjects: 250

Group type: COMPARATOR
Intervention: Angioplasty under fluoroscopy alone
Number of subjects: 250
Study: 22735650

Group type: EXPERIMENTAL
Intervention: Mechanical compression
Number of subjects: 212

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 212
Study: 19463506

Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: ramipril 5 mg/day
Number of subjects: 42
Study: 17763588

Group type: EXPERIMENTAL
Intervention: Midazolam dissolved in glucose solution (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glucose solution only with communication technique (n = 50)
Number of subjects: 100
Study: 15530676

Group type: EXPERIMENTAL
Intervention: Varicella vaccine (Varilrix)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11354528

Group type: EXPERIMENTAL
Intervention: 5 mg of melatonin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9602585

Group type: EXPERIMENTAL
Intervention: Methoxamine 10 mg i.m. (group MX)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 6% hetastarch 500 ml and crystalloid 500 ml (group HS)
Number of subjects: 62
Study: 7472698

Group type: EXPERIMENTAL
Intervention: LFG + propranolol
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Propranolol alone
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 312

Group type: COMPARATOR
Intervention: LFG + placebo
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 312

Group type: COMPARATOR
Intervention: Propranolol and placebo
Number of subjects: 312
Study: 2275207

Group type: EXPERIMENTAL
Intervention: Rumalon-injections
Number of subjects: 14

Group type: COMPARATOR
Intervention: Galvanic bath alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Rumalon-group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bone scanning
Number of subjects: 14
Study: 365920

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30821630

Group type: EXPERIMENTAL
Intervention: Panic‐focused Psychodynamic therapy (PFPP)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 161
Study: 29777234

Group type: EXPERIMENTAL
Intervention: High dairy products (≈1500 mg calcium/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low dairy products (≤600 mg calcium/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Above 30 g fiber/10MJ
Number of subjects: 80

Group type: COMPARATOR
Intervention: Below 30 g fiber/10MJ
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 80
Study: 28127938

Group type: EXPERIMENTAL
Intervention: Crushed naloxegol 25-mg tablets (suspended in water) administered orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crushed naloxegol 25-mg tablets (suspended in water) administered by nasogastric tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxegol solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available 25-mg tablet formulation
Number of subjects: 0
Study: 24549209

Group type: EXPERIMENTAL
Intervention: New method of suspension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional suction suspension
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Finger prosthesis (both types)
Number of subjects: 24
Study: 23764087

Group type: EXPERIMENTAL
Intervention: Unhealthy foods and beverages observed on campuses
Number of subjects: 4033

Group type: EXPERIMENTAL
Intervention: Healthy foods and beverages
Number of subjects: 4033
Study: 21775837

Group type: EXPERIMENTAL
Intervention: Home-based, self-obtained vaginal swabs (swab collection kits mailed to home)
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Clinic-based rescreening (made clinic appointments)
Number of subjects: 1292
Study: 19411357

Group type: EXPERIMENTAL
Intervention: Modular evidence-based treatment protocol
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard evidence-based treatment protocol
Number of subjects: 59
Study: 18005908

Group type: COMPARATOR
Intervention: Blinded placebo
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Blinded echinacea
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Unblinded open-label echinacea
Number of subjects: 720

Group type: COMPARATOR
Intervention: No doctor-patient interaction
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Standard doctor-patient interaction
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Enhanced doctor-patient interaction
Number of subjects: 720
Study: 15369126

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11844172

Group type: EXPERIMENTAL
Intervention: Ultrasound follow-up
Number of subjects: 97

Group type: COMPARATOR
Intervention: Dilatation and curettage
Number of subjects: 97
Study: 9744490

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 320 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg
Number of subjects: 9
Study: 10461420

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sulbactam-cefoperazone plus amikacin
Number of subjects: 30
Study: 2695956

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 137693

Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate (135 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate plus vitamin A (300,000 IU daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin A alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (135 mg daily) after 12 weeks
Number of subjects: 0
Study: 31426247

Group type: EXPERIMENTAL
Intervention: Microplastics (0.5 to 5 mm) quantified from sand samples taken from beaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beach location (inside versus outside the estuary)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microfibers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentration of microplastics in depositions of European shag and gulls
Number of subjects: 0
Study: 28850388

Group type: EXPERIMENTAL
Intervention: Unexpected painful stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sham stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expected painful stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-painful stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Expected pain (NRS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unexpected pain (NRS)
Number of subjects: 20
Study: 26035253

Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg oral dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 23497778

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: Follow-up IVUS
Number of subjects: 1115
Study: 21692822

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 155

Group type: COMPARATOR
Intervention: Adefovir
Number of subjects: 155
Study: 20045801

Group type: EXPERIMENTAL
Intervention: 20mg elemental zinc
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16421680

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 micro.kg(‐1).h(‐1) for 10 min followed by 0.2 micro.kg(‐1).h(‐1) for 50 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15077079

Group type: EXPERIMENTAL
Intervention: External loop recorders (ELRs)
Number of subjects: 78
Study: 11734515

Group type: EXPERIMENTAL
Intervention: Short wavelength sensitive (SWS) cone mediated sensitivity measured by blue on yellow perimetry
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Presence of soft drusen
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fellow eyes with sight threatening complications of age related macular degeneration (AMD)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Focal hyperpigmentation
Number of subjects: 126
Study: 9113633

Group type: EXPERIMENTAL
Intervention: High-AA diet (1.5 g/d of additional 20:4n‐6)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-AA diet (210 mg/d of 20:4n‐6)
Number of subjects: 10
Study: 8187319

Group type: EXPERIMENTAL
Intervention: rhIGF‐I administered subcutaneously in a dose of 40 micrograms/kg body weight
Number of subjects: 9
Study: 3048523

Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a psychiatrist
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a computer
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Self-exposure in vivo instructed by a book
Number of subjects: 84
Study: 31148412

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg administered after a high-fat and high-calorie meal
Number of subjects: 204

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg administered in fasting state
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg administered in fed state
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Comparison of pharmacokinetic characteristics between male and female subjects
Number of subjects: 204
Study: 31764147

Group type: EXPERIMENTAL
Intervention: Experimental group (muscular ankle strengthening and plantar sensory stimulation)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (foot care instructions only)
Number of subjects: 66
Study: 28782664

Group type: EXPERIMENTAL
Intervention: Breath-hold maneuver training
Number of subjects: 15
Study: 25420897

Group type: EXPERIMENTAL
Intervention: Racotumomab-alum vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23337183

Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and Commitment Therapy (ACT) with e-mail support
Number of subjects: 250

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 250
Study: 21554439

Group type: EXPERIMENTAL
Intervention: Intervention group (community pharmacy-led management)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intervention group (females)
Number of subjects: 1441
Study: 19654233

Group type: EXPERIMENTAL
Intervention: PEG-GH (1 mg for 3 weeks, then 2 mg for 3 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PEG-GH (3 mg for 3 weeks, then 6 mg for 3 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PEG-GH (4 mg for 3 weeks, then 8 mg for 3 weeks)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: PEG-GH (4 mg for 6 weeks)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 16966367

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m(2) twice daily days 1-14) plus Docetaxel (75 mg/m(2) day 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced doses of Capecitabine (950 mg/m(2)) and Docetaxel (55 mg/m(2))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full doses of Capecitabine and Docetaxel
Number of subjects: 0
Study: 16145909

Group type: EXPERIMENTAL
Intervention: Ulinastatin (group W)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 20
Study: 10670523

Group type: COMPARATOR
Intervention: Electromotive drug administration of the 3-drug association orgotein-dexamethasone-lidocaine (study 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Electromotive drug administration of the 2-drug combination verapamil-dexamethasone (study 2)
Number of subjects: 65
Study: 9487787

Group type: COMPARATOR
Intervention: PCA with piritramide (PCA-control)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intercostal blocks (ICB) with 5 ml bupivacaine 0.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Interpleural analgesia (IPA) with 20 ml bupivacaine 0.25%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (PCA, ICB, IPA)
Number of subjects: 45
Study: 8454016

Group type: EXPERIMENTAL
Intervention: Gap task
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overlap task
Number of subjects: 43
Study: 3544688

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29511130

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1578
Study: 29469337

Group type: EXPERIMENTAL
Intervention: Praziquantel (30 mg/(kg·d) for 2 days each year for three consecutive years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional liver protection therapy and symptomatic treatment
Number of subjects: 60
Study: 25516314

Group type: EXPERIMENTAL
Intervention: Liquid milk supplementation
Number of subjects: 3526

Group type: COMPARATOR
Intervention: Control group (no liquid milk)
Number of subjects: 3526
Study: 22781890

Group type: EXPERIMENTAL
Intervention: Autologous cryopreserved platelet transfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Allogeneic fresh platelet transfusion (Control)
Number of subjects: 40
Study: 20140619

Group type: EXPERIMENTAL
Intervention: Short-term therapy (4 days)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard therapy (7 days)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 106
Study: 18725489

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 626
Study: 15979218

Group type: EXPERIMENTAL
Intervention: Older adults (intervention group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Young adults (control group)
Number of subjects: 20
Study: 12739705

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg o.d.
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.i.d.
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 10561618

Group type: EXPERIMENTAL
Intervention: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha (2.5 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravaginal misoprostol (200 microg, two doses at 12-hour intervals)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intra-amniotic (15S)-15-methyl-prostaglandin F2alpha
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intravaginal misoprostol
Number of subjects: 51
Study: 8701900

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 1863049

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halothane and trichlorethylene
Number of subjects: 0
Study: 6229096

Group type: EXPERIMENTAL
Intervention: 150 mg depot medroxyprogesterone acetate (DMPA) intramuscularly
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30395789

Group type: EXPERIMENTAL
Intervention: Speed instruction group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Accuracy instruction group
Number of subjects: 144
Study: 28104188

Group type: EXPERIMENTAL
Intervention: Maternal multiple micronutrients (MMN) supplementation
Number of subjects: 2879

Group type: EXPERIMENTAL
Intervention: Socioenvironmental determinants
Number of subjects: 2879

Group type: EXPERIMENTAL
Intervention: Biomedical determinants
Number of subjects: 2879
Study: 26775606

Group type: EXPERIMENTAL
Intervention: Benralizumab (100 or 200 mg, multiple doses; 25, 100, or 200 mg every 4 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 24807628

Group type: EXPERIMENTAL
Intervention: 3-month group-based circuit exercise program combined with a 3-h educational session
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual activities
Number of subjects: 89
Study: 22421748

Group type: EXPERIMENTAL
Intervention: Adenovirus type 5 (Ad5) vector‐based vaccine
Number of subjects: 1764

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1764
Study: 19388125

Group type: EXPERIMENTAL
Intervention: Palmar bowing of the flexor retinaculum (PBFR) measured on MRI in CTS patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (21 healthy women with no symptoms of CTS)
Number of subjects: 48
Study: 17950142

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 200
Study: 15903383

Group type: EXPERIMENTAL
Intervention: Full range-of-motion training (Group 1: n = 13)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Partial range-of-motion training (Group 2: n = 8)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Mixed range-of-motion training (Group 3: n = 8)
Number of subjects: 29
Study: 12909491

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) agonist treatment for 3 months before laparoscopic surgery
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy for ovarian endometriomas
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Endometriotic stromal cells obtained from patients with GnRH agonist treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Patients without endometriomas
Number of subjects: 22
Study: 10319770

Group type: EXPERIMENTAL
Intervention: Sufentanil plus propofol titrated to electroencephalographic burst suppression
Number of subjects: 225

Group type: COMPARATOR
Intervention: Sufentanil (control group)
Number of subjects: 225
Study: 9139008

Group type: EXPERIMENTAL
Intervention: Beta-sympathomimetics (exposed group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-exposed to beta-mimetics (control group)
Number of subjects: 78
Study: 2007285

Group type: EXPERIMENTAL
Intervention: Acuvue lens (high water content ionic lens)
Number of subjects: 15

Group type: COMPARATOR
Intervention: SeeQuence lens (low water content non-ionic lens)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both lenses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Acuvue lens
Number of subjects: 15

Group type: COMPARATOR
Intervention: SeeQuence lens
Number of subjects: 15
Study: 6290132

Group type: EXPERIMENTAL
Intervention: 10 g guar gum
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 g guar gum with 25 g D-xylose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control study without guar
Number of subjects: 0
Study: 30306240

Group type: EXPERIMENTAL
Intervention: Suturing Region A (0°‐60°)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Suturing Region A + B (0°‐120°)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Suturing Region B (60°‐120°)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Suturing Region A + C (0°‐60°, 120°‐180°)
Number of subjects: 15
Study: 28978356

Group type: EXPERIMENTAL
Intervention: HADS Anxiety
Number of subjects: 6659

Group type: EXPERIMENTAL
Intervention: HADS Depression
Number of subjects: 6659
Study: 25631909

Group type: EXPERIMENTAL
Intervention: PtCr-EES
Number of subjects: 500

Group type: COMPARATOR
Intervention: PES
Number of subjects: 500
Study: 23435021

Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - Daily conjugated equine estrogens (0.625 mg) and medroxyprogesterone acetate (2.5 mg; EPT) or conjugated equine estrogens (0.625 mg; ET)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 22013792

Group type: EXPERIMENTAL
Intervention: Xiaochuangao Acupoint Paste (XAP)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo paste
Number of subjects: 142
Study: 19744406

Group type: EXPERIMENTAL
Intervention: Ketamine hydrochloride (0.5 mg/kg)
Number of subjects: 23
Study: 16777915

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3916

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 3916